Josef Vormoor

Research activity per year

External positions

Lid - HOVON study 183 - Data Monitoring Committee

1 Jan 2026 → 31 Dec 2026

Lid Education Committee - Education Committee - European Hematology Association (EHA)

1 Jan 2025 → 31 Dec 2029

Lid Trial Steering Committee - Lid Trial Steering Committee - Glo-BNHL

1 Jan 2024 → 31 Dec 2026

Lid Independent Advisory Board (2024-2029) - Lid - Experimental Cancer Medicine Center (ECMC)

1 Jan 2024 → 31 Dec 2029

Ambassadeur - Ambassadeur - SIOPe

1 Jan 2024 → 31 Dec 2026

Lid advisory board - Lid advisory board - Comprehensive Cancer Center Augsburg (CCCA)

1 Jan 2023 → 31 Dec 2026

Lid wetenschappelijke commissie - NexTGen Grand Challenge Progamme - Cancer Research UK

1 Jan 2023 → 31 Dec 2028

Lid - Specialised Working Groups (SWG) committee - European Hematology Association (EHA)

1 Jan 2023 → 31 Dec 2026

Lid advisory board - Lid advisory board - Comprehensive Cancer Center Alliance WERA

1 Jan 2022 → 31 Dec 2026

Voorzitter - Adolescents & Young Adults (AYA) task force - European Hematology Association (EHA)

1 Jan 2022 → 31 Dec 2026

Lid wetenschappelijke commissie - Beoordelingscommissie Ontwikkeling en Innovatie (O&I) - KWF

1 Jan 2022 → 31 Dec 2026

Leerstoel in divise Beeld & Oncologie - Onderzoeksactiviteiten - UMC Utrecht

1 Jul 2021 → 30 Jun 2026

Lid - Hematology Steering Committee - Innovative Therapies for Children & adolescents with Cance

1 Jan 2021 → 31 Dec 2024

Agenda lid bestuur - Agenda lid bestuur - Nederlandse Vereniging voor Hematologie (Dutch Society of

1 Jan 2021 → 31 Dec 2026

Lid advisory board - Lid advisory board - City of London CR-UK Cancer Centre

1 Jan 2019 → 31 Dec 2026

Voorzitter - Pediatric Hematology Specialised Working Group (SWG) - European Hematology Association (EHA)

1 Jan 2019 → 31 Dec 2026

Clinical Director - Clinical Director - Prinses Máxima Centrum voor kinderoncologie BV

1 Mar 2018 → 31 Dec 3999

Lid data monitoring committee - Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 - GPOH trials

1 Jan 2018 → 31 Dec 2026

Lid advisory board - Lid advisory board - Research Institute of the Childhood Cancer Centre

1 Jan 2017 → 31 Dec 2026

104 Article
10 Review article
4 Comment/Letter to the editor
3 Editorial
More
- 2 Letter

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
Vormoor, B., Savage, J., Kristunas, C., Johnson, S., Blanco, M. N. F., Shenton, G., Lancaster, D., Castleton, A., Fielding, A. K., Latif, A. L., Morley, N., Strullu, M., Tuckuviene, R., Kearns, P., Jennings, C., Barnett, S., Veal, G. J., Irving, J., Billingham, L. & Menne, T. & 1 others, Vormoor, J., Jun 2026, In: EJC Paediatric Oncology. 7, 10 p., 100489.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
A structured approach for data collection and visualization of the International Childhood Cancer Core Outcomes
van Kalsbeek, R. J., Grundeken, L. H., Mulder, R. L., Hudson, M. M., Ehrhardt, M. J., den Hartogh, J. G., Riezebos, R. J., van Tinteren, H., Kollen, W. J. W., Grootenhuis, M. A., Pieters, R., Kremer, L. C. M., van der Heiden-van der Loo, M., Aarsen, F. K., Bouts, M. J. R. J., Dierselhuis, M. P., Feijen, E. A. M., Franke, N. E., Goemans, B. F. & de Haas, V. & 24 others, Hoving, E. W., Heitink-Polle, K. M. J., Kilsdonk, E., Lindemans, C. A., Meijer, L., Merks, H., Meyer-Wentrup, F. A. G., Mavinkurve-Groothuis, A. M. C., Oomen, D. W. G. D., Partanen, M., Plasschaert, S. L. A., Schouten-Meeteren, A. Y. N., Teepen, J. C., van den Bos, C., van den Heuvel-Eibrink, M. M., van Grotel, M., van Litsenburg, R. R. L., van Noesel, M. M., van Santen, H. M., Vincent, M. J., Vormoor, H. J., van Vuurden, D., Wijnen, M. H. W. A. & Zsiros, J., Jun 2025, In: EJC Paediatric Oncology. 5, 100239.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
10 Downloads (Pure)
Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325]
Langenberg, K. P. S., Meister, M. T., Bakhuizen, J. J., Boer, J. M., van Eijkelenburg, N. K. A., Hulleman, E., Ilan, U., Looze, E. J., Dierselhuis, M. P., Lugt, J. V. D., Breunis, W., Schild, L. G., Ober, K., van Hooff, S. R., Scheijde-Vermeulen, M. A., Hiemcke-Jiwa, L. S., Flucke, U. E., Kranendonk, M. E. G., Wesseling, P. & Sonneveld, E. & 34 others, Punt, S., Boltjes, A., van Dijk, F., Verwiel, E. T. P., Volckmann, R., Hehir-Kwa, J. Y., Kester, L. A., Koudijs, M. M. J., Waanders, E., Holstege, F. C. P., Vormoor, H. J., Hoving, E. W., Noesel, M. M. V., Pieters, R., Kool, M., Stumpf, M., Blattner-Johnson, M., Balasubramanian, G. P., Van Tilburg, C. M., Jones, B. C., Jones, D. T. W., Witt, O., Pfister, S. M., Jongmans, M. C. J., Kuiper, R. P., de Krijger, R. R., Wijnen, M. H. W., den Boer, M. L., Zwaan, C. M., Kemmeren, P., Koster, J., Tops, B. B. J., Goemans, B. F. & Molenaar, J. J., 15 May 2025, In: European Journal of Cancer. 221, 115423.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
3 Downloads (Pure)
Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment
Ferrao Blanco, M. N., Kazybay, B., Belderbos, M., Heidenreich, O. & Vormoor, H. J., 2025, In: Leukemia. 39, 11, p. 2622–2639 18 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
1 Downloads (Pure)
Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia
Derevyanko, P. K., Swart, L. E., Mata Casimiro, L. D., van Oort, A., Du Plessis, M., van den Brink, L., Ashtiani, M., Zwaan, C. M., Krippner-Heidenreich, A., Bonifer, C., Schiffelers, R. M., Vormoor, J. J., Kellaway, S. & Heidenreich, O., 11 Dec 2025, In: Blood. 146, 24, p. 2963-2978 16 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
1 Downloads (Pure)

Josef Vormoor

Personal profile

External positions

Collaborations and top research areas from the last five years

Dive into details

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

A structured approach for data collection and visualization of the International Childhood Cancer Core Outcomes

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325]

Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment

Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia

Josef Vormoor

Personal profile

External positions

Collaborations and top research areas from the last five years

Research output

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

A structured approach for data collection and visualization of the International Childhood Cancer Core Outcomes

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325]

Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment

Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia